DaVita Inc. ($DVA) Stock Forecast: Up 5.4% Today

What is DaVita Inc.?

DaVita Inc. is a healthcare company specializing in kidney dialysis services. The stock had a strong bullish movement today, outperforming the broader market.

Why is DaVita Inc. going up?

DVA stock is up 5.4% on Jun 4, 2026 14:02

• DaVita's stock rallied 3.80% today, breaking a three-day losing streak and showcasing resilience amidst a general downturn in the stock market.
• The recent 21.4% gain over three months can be attributed to strong Q1 2026 results, increased treatment volumes, and raised guidance, positioning the stock as a "Strong Buy" according to analysts.
• Despite potential challenges like rising operating expenses and reliance on commercial insurance plans, DaVita's improving fundamentals and efficient operations have contributed to its positive market performance.
• The positive momentum in DaVita's stock price contrasts with its recent underperformance compared to competitors, highlighting the volatility and competitive nature of the healthcare industry.

DVA Price Chart

DVA Technical Analysis

DVA News

Best Growth Stocks to Buy for June 4th

This article identifies three growth stocks—H&R Block (HRB), DaVita Inc. (DVA), and Valero Energy Corporation (VLO)—that analysts recommend for June 4th. All three companies hold a Zacks Rank #1 (Strong Buy) and demonstrate strong growth characteristics, including favorable PEG ratios and recent positive adjustments to their earnings estimates. Investors can find detailed analysis and further recommendations from Zacks Investment Research.

https://sg.finance.yahoo.com/news/best-growth-stocks-buy-june-093400795.html

DaVita Inc. stock outperforms competitors on strong trading day

DaVita Inc. (DVA) saw its stock rally 3.80% to $195.03 on Wednesday, despite a general downturn in the stock market where both the S&P 500 and Dow Jones Industrial Average fell. This gain broke a three-day losing streak for DaVita. The strong performance highlights its resilience compared to the broader market.

https://www.marketwatch.com/data-news/davita-inc-stock-outperforms-competitors-on-strong-trading-day-2c09a0a3-a20a83199eb0?mod=goog_fin_scmw

DaVita Gains 21.4% in Three Months: How Should You Play the Stock?

DaVita (DVA) shares have seen a significant 21.4% gain over the past three months, outperforming its industry and the S&P 500, driven by strong Q1 2026 results, increased treatment volumes, and raised guidance. The company benefits from its core dialysis franchise, value-based care initiatives, and robust cash flow, positioning it as a "Strong Buy" according to Zacks. However, rising operating expenses and reliance on commercial insurance plans present potential challenges, though its current valuation may not fully reflect its improving fundamentals.

https://www.tradingview.com/news/zacks:7ccd19666094b:0-davita-gains-21-4-in-three-months-how-should-you-play-the-stock/

SOLV Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides an in-depth financial analysis of Solventum Corp (SOLV), detailing its revenue breakdown, profitability margins, and a comparison with competitors. MedSurg is identified as the largest revenue contributor, accounting for 61.5% of total sales. The company's strong gross margin of 54.66% and ROE of 34.80% highlight its efficiency, while benchmarking against DVA and BTSG positions SOLV as a leader in the Medical Equipment, Supplies & Distribution industry.

https://intellectia.ai/en/stock/SOLV/financials

DaVita Inc. stock underperforms Tuesday when compared to competitors

Shares of DaVita Inc. (DVA) fell by 1.01% on Tuesday, closing at $187.89, despite a positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, making this DaVita's third consecutive day of losses.

https://www.marketwatch.com/data-news/davita-inc-stock-underperforms-tuesday-when-compared-to-competitors-5b0e9035-4a235fb23686?mod=mw_quote_news

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

DaVita Inc. Price History

05.01.2026 - DVA Stock was up 5.4%

• DaVita's stock price surged after the company announced an impressive 2026 adjusted EPS forecast, exceeding market expectations and showcasing strong growth potential.
• Analysts raised their price target for DaVita, citing confidence in the company's future performance and outlook, further boosting investor sentiment.
• The strategic expansion initiatives, such as the partnership with Ares Management and Elara Caring for a kidney-focused home-based care model, have also contributed to the positive market movement.
• Despite potential challenges like the end of ACA subsidies, DaVita's focus on reducing debt, share buybacks, and operational improvements have instilled optimism among investors, leading to the bullish trend in the stock price.

06.01.2026 - DVA Stock was down 5.4%

• Following a recent increase in stock price, DaVita Inc. (DVA) encountered a considerable downward trend today, potentially influenced by investor uncertainty surrounding future earnings stability.
• The apprehensive outlook on DVA might have been impacted by its earnings decrease over the past year, despite optimistic projections for robust yearly growth over the next three years.
• Although the National Pension Service acquired a new share in DVA in the third quarter and the market responded positively to Q4 earnings, concerns regarding reimbursement, regulatory shifts, and financial uncertainties persisted, contributing to the downward movement in the market today.

04.05.2026 - DVA Stock was up 5.4%

• DaVita's stock rallied 3.80% today, breaking a three-day losing streak and showcasing resilience amidst a general downturn in the stock market.
• The recent 21.4% gain over three months can be attributed to strong Q1 2026 results, increased treatment volumes, and raised guidance, positioning the stock as a "Strong Buy" according to analysts.
• Despite potential challenges like rising operating expenses and reliance on commercial insurance plans, DaVita's improving fundamentals and efficient operations have contributed to its positive market performance.
• The positive momentum in DaVita's stock price contrasts with its recent underperformance compared to competitors, highlighting the volatility and competitive nature of the healthcare industry.

06.04.2026 - DVA Stock was up 23.8%

• The strong bullish movement in DaVita's stock price can be attributed to the company's robust Q1 2026 performance, beating revenue and EPS estimates.
• DaVita's increased annual profit forecast and raised adjusted EPS guidance for the year have instilled confidence in investors, reflecting strong demand for its dialysis services.
• Analysts and insiders may view DaVita's emphasis on cost efficiency and improved operational performance as key drivers for the stock's positive momentum.
• Despite concerns about revenue growth deceleration, DaVita's focus on profitability and operational efficiency seems to have resonated well with the market, leading to the bullish market movement.

06.04.2026 - DVA Stock was up 23.4%

• The stock of DaVita experienced a strong bullish movement following an impressive Q1 2026 earnings report, surpassing market expectations for both earnings per share (EPS) and revenue. This positive performance was fueled by substantial year-over-year growth in earnings and revenue, as well as widened margins.
• The decision of the company to raise its adjusted EPS outlook for 2026 signals confidence in its sustained financial robustness and operational efficiency, instilling heightened investor confidence and lifting the stock price.
• DaVita's strategic efforts, including enhanced reimbursement rates, share repurchases, and the incorporation of AI tools in its nephrology platform, have contributed to an optimistic outlook and attracted momentum traders exploring opportunities in the healthcare sphere.
• Despite the market's positive reception of the company's emphasis on cost efficiency and enhanced operational performance, potential challenges associated with treatment volumes and patient mortality risks could still impact future performance, emphasizing the importance of continuous vigilance and strategic planning.

12.01.2026 - DVA Stock was up 5.5%

• DaVita's stock experienced a strong bullish movement due to several key factors:
• Overcoming skepticism related to GLP-1 drugs and successfully transitioning to a value-based integrated kidney care model.
• Aggressive share buybacks and a clarified regulatory environment boosting investor confidence.
• Strong financial performance, including profitability in the Integrated Kidney Care segment, driving the stock to new all-time highs.
• The positive outlook for DaVita is further supported by Wall Street analysts' consensus "Hold" rating, with UBS maintaining a "Buy" rating and a $190 price target, indicating a potential upside of 34.9%.
• The company's ability to deliver better-than-expected Q4 2025 results, surpassing analyst expectations for revenue and non-GAAP profit, has further fueled investor optimism and contributed to the bullish market movement.

13.02.2026 - DVA Stock was down 5.2%

• DaVita's stock experienced a bearish movement likely due to market skepticism concerning downbeat forecasts and concerns over the company's business model and financial performance.
• Despite DaVita's strong Q4 earnings and optimistic FY2026 guidance, negative sentiment from Wall Street analysts regarding declining sales and other issues may have contributed to the stock's decline.
• The market may be reacting to the overall cautious outlook on DaVita's future growth potential, as concerns were raised about unpopular stocks and their underlying challenges.
• The bearish movement could also be influenced by broader market trends or sector-specific factors impacting healthcare companies, leading investors to reevaluate their positions in DaVita.

04.01.2026 - DVA Stock was up 6.6%

• Collaborating with Elara Caring to expand home-based care options for dialysis patients has sparked investor optimism and signaled a shift towards integrated care models and increased access to in-home treatment.
• The company's strong Q4 results, exceeding revenue and earnings expectations, coupled with a positive forecast for 2026, have increased investor confidence and boosted the stock price.
• DaVita's share repurchase and optimistic guidance for the upcoming year demonstrate confidence in its strategic direction and potential for sustained growth, contributing to the current bullish market trend.

04.01.2026 - DVA Stock was up 9.2%

• Company's price target was increased to $190 from $186 by UBS, noting strong 2026 guidance with anticipated growth in operating income and EPS, as well as benefits from the Elara Caring investment.
• Partnership with Elara Caring presents a novel approach to kidney and home care services, potentially broadening in-home health options for dialysis patients and promoting more integrated care models.
• Exceeding expectations, DaVita reported impressive fourth-quarter results with revenue hitting $3.62 billion and adjusted profit per share at $3.40, driving a substantial stock surge.
• Exceptional 2026 adjusted earnings per share forecast of $14.30, surpassing previous analyst estimates, has increased investor confidence in DaVita's future outlook.

03.01.2026 - DVA Stock was up 20.2%

• DaVita's robust Q4 performance and positive 2026 guidance bolstered investor confidence, leading to a 25% increase in its stock value.
• The 14.2% decline in short interest suggests a change in sentiment toward the company after its solid financial showing.
• Enhanced margins, driven by increased revenue per treatment and strategic acquisitions, contributed to the favorable market response and stock price appreciation.
• DaVita's commitment to enhancing patient care, reducing mortality rates, and pursuing future growth through strategic moves, as highlighted in the earnings call, further reinforced investor confidence in the company's future prospects.

05.04.2026 - DVA Stock was up 5.1%

• The stock of DaVita has shown a strong bullish movement, surpassing its competitors and the overall market during a day with bearish trading conditions.
• Investor sentiment is positive regarding DaVita's transition to value-based kidney care, particularly in the area of integrated kidney care segment profitability and sustainable growth.
• Ahead of the first-quarter earnings release, analysts predict a slight deceleration in revenue growth, although DaVita has a consistent record of meeting Wall Street's expectations, contributing to the current optimistic market outlook.
• Recent updates on institutional ownership adjustments, such as Mitsubishi UFJ Trust & Banking Corp reducing its stake in DaVita, may have had some impact on market dynamics. However, overall confidence in the company's performance remains strong.

07.04.2026 - DVA Stock was up 5.1%

• DaVita's stock surged by over 20% after reporting a blowout Q1 earnings beat and raising its full-year guidance, showcasing strong financial performance and investor confidence.
• The company's strategic focus on AI-enabled nephrology and operational discipline, as highlighted in its Q1 results, is attracting significant market interest and positioning DaVita for sustainable growth.
• Participation in the BofA Securities 2026 Health Care Conference and the overall positive sentiment in the healthcare sector, as seen in the U.S. stock indexes' gains, further contributed to the bullish movement in DaVita's stock.
• The market's reaction indicates that investors are optimistic about DaVita's future prospects and the company's ability to deliver strong financial results, driving the stock to reach an all-time high.